Table 3.

Nonhematologic grade 3/4 toxicities of treated patients

n (%)All patients (N = 57)Responders OR (N = 23)Nonresponders NR (N = 34)P-value OR vs. NR
Pulmonary congestion27 (47%)10 (43%)17 (50%).629
Renal failure11 (19%)5 (22%)6 (18%).701
Prolonged hypotension13 (23%)5 (22%)8 (24%).874
Hyperbilirubinemia8 (14%)5 (22%)3 (9%).181
Diarrhea7 (12%)3 (13%)4 (12%).885
Cardiac toxicity1 (2%)1 (4%)0.404
Confusion4 (7%)3 (13%)1 (3%).289
Skin rash2 (4%)2 (9%)0.158
Autoimmunity (vitiligo)1 (2%)1 (4%)0.404
Mortality (cardiac arrest; one additional patient died during preconditioning)1nanana

NOTE: Adverse events were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 3.0.

Abbreviation: na, not applicable.